- This event has passed.
BioBusiness Insights: Breakthrough Technologies and Opportunities for Australia
October 15, 2020 @ 9:00 am - 10:00 am AEDT
Event Navigation
This is Session 6 in the BioBusiness Insights: Opportunities in Regenerative Medicine series. Find out more about the full series.
In this presentation Aislinn Treloar, Business Development Manager at Exopharm Ltd will talk about some of the work Exopharm are doing and what challenges, regulations and commercial issues they face. Aislinn will provide an insight into why some of Exopharm’s approaches vary from that of other organisations in the industry.
Session 6 Details
Date: Thursday 15 October 2020
Time: 9:00 am – 10:00 am AEDT
Format: This event will be delivered on a virtual platform – you will receive a link to join via a confirmation email following registration.
Registration:
Single session: Members $35; Non-members $45
Unsure if your organisation is a member? Check our member directory.
Registered? Submit a question for Session 6 ahead of time.
Speaker
Aislinn Treloar, Business Development Manager, Exopharm Ltd
Panelist
Dr Ian Dixon, Managing Director & Founder, Exopharm Ltd
Series Facilitator
Silvio Tiziani, CEO, CCRM Australia
Thanks to our Premier Sponsor for this event series, the State Government of Victoria.
Thanks to our Supporting Sponsor for this event, Cortellis.
BioBusiness Insights is delivered in collaboration with the Centre for Commercialization of Regenerative Medicine (CCRM) Australia.
Cancellation Policy:
Full refund given up to 3 days prior to the event.
No refunds within 3 days of the event.
Aislinn Treloar, Business Development Manager, Exopharm Ltd
Aislinn has been working as a business development professional in the life sciences industry for the past 5 years. She understands the challenges that many early-stage Australian biotechnology companies face and has supported the commercialisation of a variety of innovative healthcare technologies. She is currently the Business Development Manager at Exopharm Ltd. Prior to that she was Senior Business Development Associate at Bio-Link Australia, where she facilitated technology evaluation, commercial opportunity assessment and partnering.
Aislinn holds a Masters’ degree from the University of Toronto’s Department of Medical Biophysics, and a Bachelor of Arts & Science (Economics and Molecular Biology) from McGill University.
Aislinn holds a Masters’ degree from the University of Toronto’s Department of Medical Biophysics, and a Bachelor of Arts & Science (Economics and Molecular Biology) from McGill University.
Dr Ian Dixon, Managing Director & Founder, Exopharm Ltd
Dr Ian Dixon has a PhD in biomedical engineering from Monash University, an MBA from Swinburne University and professional engineering qualifications. Ian has been successful in translating technology challenges into valuable businesses and respected intellectual property.
Ian is a co-inventor of Exopharm’s LEAP manufacturing technology and a co-inventor of Fortrexo, part of Exopharm’s EEV pipeline.
Ian brings to Exopharm an extensive technical, commercial and entrepreneurial background.
Before founding Exopharm in 2013, Ian co-founded Cynata Inc, the owner of the Cymerus stem cell technology now being commercialised by ASX-listed clinical-stage Cynata Therapeutics Ltd (ASX:CYP).
He is also non-executive director of NYRADA Inc. (ASX:NYR), co-inventor of Nyrada PCSK9 inhibitor drug NYX-330, and founder and investor of Cardio Therapeutics Pty Ltd.
Ian was previously a founding director of Sydney-based Noxopharm Ltd (ASX:NOX) and non-executive director of Melbourne unlisted company Cell Therapies Pty Ltd. Ian currently serves as a part-time director of Medigard Ltd (ASX:MGZ).
Ian is a co-inventor of Exopharm’s LEAP manufacturing technology and a co-inventor of Fortrexo, part of Exopharm’s EEV pipeline.
Ian brings to Exopharm an extensive technical, commercial and entrepreneurial background.
Before founding Exopharm in 2013, Ian co-founded Cynata Inc, the owner of the Cymerus stem cell technology now being commercialised by ASX-listed clinical-stage Cynata Therapeutics Ltd (ASX:CYP).
He is also non-executive director of NYRADA Inc. (ASX:NYR), co-inventor of Nyrada PCSK9 inhibitor drug NYX-330, and founder and investor of Cardio Therapeutics Pty Ltd.
Ian was previously a founding director of Sydney-based Noxopharm Ltd (ASX:NOX) and non-executive director of Melbourne unlisted company Cell Therapies Pty Ltd. Ian currently serves as a part-time director of Medigard Ltd (ASX:MGZ).
Silvio Tiziani, CEO, CCRM Australia
Silvio Tiziani has played a key role in the establishment of Centre for Commercialisation of Regenerative Medicine (CCRM) Australia with the support of Canada’s CCRM, the Victorian Government and MTPConnect. Silvio is also Director, External Strategy and Planning at the Australian Regenerative Medicine Institute (ARMI). Silvio’s extensive knowledge of the research landscape is well utilised with his networks within the industry, international organisations and state and federal governments.
Silvio has extensive experience in private and public organisations, with a focus on laboratory-based services in government, private organisations, healthcare and research/academia.
In addition to qualifications that include a Bachelor of Science from Swinburne University and a Masters of Business Administration from Monash University, Silvio is also a graduate of the Australian Institute of Company Directors (GAICD). Silvio has extensive experience in financial analysis and budget management, business development, strategic planning and corporate governance along with strong interpersonal skills to lead staff.
Silvio also chairs the Ausbiotech Regenerative Medicine Advisory Group. Comprising leading representatives from industry and academia within the Australian regenerative medicine the Group provides specialist advice to Ausbiotech, Australia’s member-based biotechnology organisation, a peak body that promotes the global growth of Australian biotechnology.
Silvio has extensive experience in private and public organisations, with a focus on laboratory-based services in government, private organisations, healthcare and research/academia.
In addition to qualifications that include a Bachelor of Science from Swinburne University and a Masters of Business Administration from Monash University, Silvio is also a graduate of the Australian Institute of Company Directors (GAICD). Silvio has extensive experience in financial analysis and budget management, business development, strategic planning and corporate governance along with strong interpersonal skills to lead staff.
Silvio also chairs the Ausbiotech Regenerative Medicine Advisory Group. Comprising leading representatives from industry and academia within the Australian regenerative medicine the Group provides specialist advice to Ausbiotech, Australia’s member-based biotechnology organisation, a peak body that promotes the global growth of Australian biotechnology.
